trending Market Intelligence /marketintelligence/en/news-insights/trending/drhjngv8djuwtskmuf7ahw2 content esgSubNav
In This List

Matinas BioPharma appoints vice chairman

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Matinas BioPharma appoints vice chairman

Matinas BioPharma Holdings Inc. appointed Patrick LePore as vice chairman of the board.

LePore served as the CEO, chairman and president of Par Pharmaceuticals Inc. from 2006 to 2012.

Matinas Biopharma said in a Sept. 6 news release that Lepore oversaw the sale of Par Pharmaceuticals to Texas Pacific Group for $2 billion in November 2012 and was appointed as the chairman. He oversaw the new company's $8 billion sale to Endo International PLC in 2015.

Matinas BioPharma is a clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for orphan indications.